# **U** NOVARTIS

### Reclast<sup>®</sup> (zoledronic acid) Injection

### FDA Joint Reproductive Health Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting on the long term use of bisphosphonates for the treatment and prevention of osteoporosis

### September 9, 2011

- Document type : Briefing Document
- Document status: Final
- Release date: August 5, 2011
- Number of pages: 32

**Novartis Pharmaceuticals Corporation** 

AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION

\_\_\_\_\_

\_\_\_\_

Та		f contents	2
		of tables	
		of figures	
1		utive Summary	
1		luction	
2	2.1	Osteoporosis and Osteopenia.	
	2.1 2.2	Reclast (zoledronic acid)	
3			/
3		acy in Reclast Clinical Trial Program for Post-menopausal Osteoporosis and openia	8
	3.1	Reclast Pivotal Fracture Trial in postmenopausal osteoporosis (H2301)	
	3.2	Reclast Pivotal Fracture Trial Extension up to 6 years (H2301E1)	11
	3.3	Reclast Recurrent Fracture Trial in patients with recent hip fracture (H2310)	14
	3.4	Reclast Prevention of Bone Loss (N2312)	15
4	Revie	ew of Reclast safety data	17
	4.1	Bone safety	18
	4.2	ONJ Overview	18
	4.3	Reclast clinical trial data and ONJ	19
	4.4	Atypical subtrochanteric femur fractures overview	20
	4.5	Reclast clinical trial data and "atypical" subtrochanteric femur fractures	
	4.6	Post-marketing experience	21
	4.7	Post-marketing reports of ONJ	21
	4.8	Post-marketing reports of "atypical" subtrochanteric femur fractures	21
	4.9	Novartis on-going safety evaluation program	21
5	Overa	all benefit/risk of Reclast in light of the questions being posed by FDA	22
6	Conc	lusions	24
7	Refer	ences	24
AP	PEND	ICES	27
	Narra	tives of Adjudicated ONJ cases from Reclast Clinical Trials	27
	Recla	st <sup>®</sup> US Prescribing Information	28

### List of tables

Table 3-1	Summary of supportive efficacy and safety data from completed studies	.8
Table 3-2	Rates of fracture in men and women with an incident hip fracture over median 1.9 years follow-up (H2310)	15

List of figures		
Figure 3-1	Effect of zoledronic acid treatment on the risk of vertebral fractures – Study H2301 (mITT <sup>+</sup> )	.10
Figure 3-2	Effect of zoledronic acid treatment on the risk of hip and other clinical fractures over time – Study H2301 (ITT)	.11
Figure 3-3	Percentage change from year 0 in femoral neck BMD over 6 years (H2301E1 ITT population)	.12
Figure 3-4	P1NP (ng/mL) by visit over 6 years – Study H2301E1 (ITT)	.13
Figure 3-5	Morphometric vertebral fractures, Years 3–6–Study H2301E1 (ITT)	.14
Figure 3-6	Effect of Reclast treatment on lumbar spine BMD in postmenopausal women with osteopenia	.16

Novartis	AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION
Sponsor Briefing D	Document

List of abbreviations	
AE	Adverse Event(s)
ASBMR	American Society for Bone and Mineral Research
BMD	Bone Mineral Density
BP	Bisphosphonate(s)
BSAP	Bone Specific Alkaline Phosphatase
BTM	Bone Turnover Marker(s)
CI	Confidence Interval
СТ	Computed Tomography
β-CTX	C-terminal telopeptide of Type 1 collagen
FDA	Food and Drug Administration
FN	Femoral Neck
FPPS	farnesyl diphosphate synthase
GI	Gastrointestinal
i.v.	Intravenous
MedDRA	Medical Dictionary for Regulatory Activities
NNT	Number Needed to Treat
NNH	Number Needed to Harm
ONJ	Osteonecrosis of the Jaw
OP	Osteoporosis
P1NP	n-terminal propeptide of type 1 collagen
PBO	Placebo
РМО	Post-menopausal osteoporosis
pt-yrs	patient-years
SAE	Serious Adverse Event(s)
USPI	United States Prescribing Information

#### 1 Executive Summary

- There are 44 million women and men with osteoporosis (OP) and osteopenia in the US. This population has an increased risk for OP-related fractures which have significant associated morbidity and mortality. OP related fractures are estimated to cost over \$17 billion annually.
- Reclast<sup>®</sup> (zoledronic acid) for infusion, marketed by Novartis Pharmaceuticals Corporation (Novartis), is a third generation bisphosphonate (BP) approved for the treatment and prevention of OP, and the treatment of Paget's Disease of the bone. In OP, intravenous (i.v.) infusion of 5 mg annually provides a durable antiresorptive effect with beneficial effects on fracture risk reduction, increases in bone mineral density (BMD) and markers of bone turnover.
- Reclast is effective in the treatment and prevention of OP.
  - Reclast treatment has been shown to provide significant reductions in morphometric vertebral (70%) and hip fracture (41%), in addition to non-vertebral (25%), clinical (33%), and clinical vertebral (77%) fractures in postmenopausal osteoporotic women over a 3 year course of therapy.
  - In osteoporotic women treated for 3 years with Reclast, 3 years of additional therapy (6 years in total) resulted in a statistically significant increase in femoral neck (FN) BMD and a 49% reduction in the risk of new morphometric vertebral fractures compared with women who stop Reclast therapy after 3 years, suggesting that the protective effect against osteoporotic fractures may persist.
  - Post-hoc analyses of patients treated for 6 years with Reclast provide information on subgroups that may benefit most from continued therapy (hip OP, T-score  $\leq$  -2.5; or a new vertebral fracture while on therapy).
- The long-term safety profile of Reclast therapy (up to 6 years) has been established through evaluation in controlled clinical trials and in post-marketing pharmacovigilance; including evaluation of skeletal events of interest (osteonecrosis of the jaw [ONJ] and atypical subtrochanteric femur fracture). Current labeling describes the reported and potential risks with Reclast therapy and provides recommendations to practitioners regarding continued therapy.
- While treating physicians have the option to interrupt therapy in individual cases based on a benefit/risk evaluation, there is no evidence to support a blanket recommendation of a drug holiday for all patients who receive Reclast therapy. Decisions to continue or interrupt Reclast therapy should be made on a patient-specific basis with consideration of clinical factors and BMD or bone turnover markers (BTM) to guide decision making.

#### 2 Introduction

The Food and Drug Administration (FDA) has convened a joint meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee to "discuss the benefits and risks of long-term bisphosphonate use for the treatment and prevention of osteoporosis, in light of the emergence of the safety concerns of osteonecrosis of the jaw and atypical femur fractures that may be associated with the longterm use of bisphosphonates." The sponsors of the currently marketed BP products for OP have been invited to participate. Novartis was asked to provide responses to questions posed by the FDA:

- Provide an opinion and discussion of whether the efficacy and safety data support a long-term duration of use (i.e., > 3 years) for Reclast (zoledronic acid) Injection.
- Provide an opinion and discussion of whether either restricting the duration of use or implementing a drug holiday may be beneficial for patients requiring long-term treatment.

This document presents efficacy and safety data from the Reclast post-menopausal osteoporosis (PMO)/osteopenia development program to inform the benefit-risk assessment of Reclast, in the context of the available information on ONJ and atypical subtrochanteric femur fractures from clinical trials and post-marketing surveillance. These data will form the basis of Novartis responses to the questions posed.

#### 2.1 Osteoporosis and Osteopenia

OP is a chronic, progressive disorder in which bone resorption exceeds formation, resulting in decreased bone mass and deterioration of the microarchitecture of bone. This results in decreased bone strength and increased susceptibility to fracture. OP is a silent disease until it is complicated by fractures (NIH 2001).

In the United States, approximately 10 million Americans have OP and another 34 million have low bone mass (osteopenia) and are at risk of developing OP; 80% of these are women. Women with low bone mass have an increased fracture risk (compared with those with normal bone density) unless bone loss is prevented (NOF 2010).

Over 2 million osteoporotic fractures are reported each year, which is greater than the annual incidence of heart attack, stroke, and breast cancer, combined (NOF 2008, AHA 2008, ACS 2008). Fractures related to OP will affect approximately 1 of every 2 women and 1 of every 5 men over the age of 50 in the United States. The most common fractures are those of the spine, hip and wrist. Hip fractures result in 10 to 20 percent excess mortality within one year. Over half of women who sustain a hip fracture do not return to their previous functional state and become dependent on others for their daily activities (Bentler 2009, Cauley 2000). Additionally, hip fractures are associated with a 2.5 fold increased risk of future fractures. Mortality is also increased following spine fractures, which can cause significant complications including back pain, height loss and kyphosis. Multiple thoracic fractures may result in restrictive lung disease, and lumbar fractures may alter abdominal anatomy, leading to abdominal pain, distention and constipation (NOF 2010).

Annual US direct medical costs associated with new osteoporotic fractures are over \$19 billion. By the year 2025, these costs are projected to rise by as much as 50%, to over \$25 billion, reflecting an increase in the US population of persons aged 50 years and over (NOF 2010).

Over the past two decades, BP drugs have assumed a significant role in the prevention and treatment of OP because of their demonstrated ability to increase BMD and reduce the risk of fractures and their associated morbidity and mortality.

#### 2.2 Reclast (zoledronic acid)

Intravenous Reclast as an annual infusion was developed to offer the opportunity for improved compliance, without the potential for gastrointestinal (GI) irritation associated with oral BP.

Reclast is a third generation BP with a high binding affinity for human mineralized bone. Like other BP, Reclast binds to all bone surfaces with the greatest deposition on surfaces which are in the process of mineralization at the time of infusion. Reclast, as an i.v. infusion, is administered at a lower dose than oral BP (e.g., 70 mg alendronate weekly) where only about 1% of the drug enters the blood stream after each dose due to poor GI absorption (Fosamax<sup>®</sup> United States Prescribing Information [USPI] 2011). After i.v. infusion, peak Reclast blood levels occur at the end of the infusion period followed by a rapid decline in circulating concentrations to <1% of peak levels by 24 hours after dosing. Mean urinary excretion of unmetabolized Reclast is 39% over the 24 hours following infusion, indicating that approximately 61% of the Reclast dose is deposited on the bone surfaces within 24 hours (Reclast USPI 2011).

Delivery of the full annual dose (5 mg) at one time supports a rapid onset of the antiresorptive effect, while the systemic exposure to Reclast at biologically relevant concentrations is limited to a window of approximately 24 hours following annual infusion. With oral BP it may take weeks or months to achieve similar coverage of the bone compared to i.v. Reclast administration (Saag 2007).

Following deposition in the mineralized matrix, BP exert a long-term effect on bone resorption (Fosamax USPI 2011, Actonel<sup>®</sup> USPI 2011, Boniva<sup>®</sup> USPI 2011). During the process of bone resorption, BPs are internalized by fluid-phase endocytosis by the osteoclasts (Thompson 2006, Coxon 2008). Within the osteoclast, BP inhibit the enzyme, farnesyl diphosphate synthase (FPPS), which reduces bone resorption by the osteoclasts and promotes their apoptosis (Russell 2007). The process of bone remodeling represents the main mechanism by which BP are eliminated from the skeleton. The antiresorptive effect of Reclast (and other BP) persists while sufficient drug is left on the bone surface to inhibit osteoclast function whenever bone resorption is initiated. As a result, the duration of the bone-protective effect of Reclast and other BP in a given patient depends on the intensity of bone turnover (bone remodeling), with higher bone turnover resulting in more rapid clearance of the BP and thus a shorter duration of action (Russell 2008).

Based on biomarkers of bone resorption (serum C-terminal telopeptide of Type 1 collagen [ $\beta$ -CTx]) and bone formation (serum n-terminal propeptide of type 1 collagen [P1NP] and bone specific alkaline phosphatase [BSAP]), an infusion interval of 1 year for the 5 mg dose

appears to be appropriate for most postmenopausal osteoporotic patients to maintain the biomarkers of bone turnover within the pre-menopausal range (Black 2007). For postmenopausal patients who are osteopenic, an infusion interval of every other year is recommended due to persistent increases in BMD and changes in BTM beyond 1 year (McClung 2009). It is important to note, however, that once bound to bone, all BP have a long duration of effect (Fosamax USPI 2011; Actonel USPI 2011; Boniva USPI 2011).

Reclast was approved for the treatment of postmenopausal OP in 2007. For this indication it is administered annually as a 5 mg i.v. infusion.

Currently, Reclast is approved in the US for the following indications.

- Treatment of Paget's disease of bone in men and women (approved 16-Apr-2007)
- Treatment of OP in postmenopausal women (approved 17-Aug-2007)
- Treatment to increase bone mass in men with OP (approved 19-Dec-2008)
- Treatment and prevention of glucocorticoid-induced OP in patients expected to be on glucocorticoids for at least 12 months (approved 13-Mar-2009)
- Prevention of OP in postmenopausal women (approved 29-May-2009)

Zoledronic acid, the active ingredient in Reclast, is also approved as Zometa<sup>®</sup> with a different dose and dosing regimen for use in advanced cancer indications. As the Zometa data does not inform the benefit/risk of Reclast for OP/osteopenia, the Zometa clinical data in cancer patients will not be reviewed in this Briefing Book.

### 3 Efficacy in Reclast Clinical Trial Program for Postmenopausal Osteoporosis and Osteopenia

Supportive data to address the questions posed by the FDA are taken from completed phase III and IIIb trials in adult patients with PMO, incident hip fracture, and osteopenia (summarized Table 3-1).

Table 3-1 Summary of supportive encacy and safety data non-completed studies							
Study	Population	Duration	Primary Objective	Number of Subjects (ITT)			
Pivotal Fracture Trial (H2301)	Osteoporotic post- menopausal women	3 years	Reduction of morphometric vertebral and hip fracture	7736 ZA: 3875 Placebo: 3861			
Pivotal Fracture Trial Extension 1 (H2301E1)	Osteoporotic post- menopausal women	3 years	% change in femoral neck BMD at Year 6 relative to Year 3	2456 Z6: 616 Z3P3: 617 P3Z3: 1223			
Recurrent Fracture Trial (L2310)	Osteoporotic women and men with an incident hip fracture	Event driven: 5 years with a mean follow up of 1.9 years	Reduction of clinical fractures after hip fracture	2127 ZA: 1065 Placebo: 1062			
Prevention of Bone Loss (N2312)	Post- menopausal women with	2 years	% change from baseline in lumber spine BMD	581 ZA: 379			

 Table 3-1
 Summary of supportive efficacy and safety data from completed studies

Study	Population	Duration	Primary Objective	Number of Subjects (ITT)	
	osteopenia			Placebo: 202	
ZA: zoledronic acid (Reclast); Z6: patients treated with ZA for up to 6 years; Z3P3: patients treated with 3 years of ZA followed by 3 years of placebo; P3Z3: patients treated with 3 years of placebo followed by 3 years of ZA					

## 3.1 Reclast Pivotal Fracture Trial in postmenopausal osteoporosis (H2301)

Women with PMO are at a markedly increased risk for fractures of the spine, hip and wrist. Prevention of these fragility fractures is the goal of OP therapy. The Pivotal Fracture Trial Study (H2301) investigated the efficacy and safety of Reclast compared with placebo (PBO) in reducing vertebral and hip fractures over 3 years in PMO patients. The results of this trial have been published in the New England Journal of Medicine (Black 2007) and serve as the basis of the approved labeling for the treatment of PMO.

This trial was a 3-year multicenter, randomized, double-blind, PBO-controlled trial in women with PMO. A total of 7736 women were enrolled in 27 countries. Patients were randomly assigned to receive Reclast or PBO infusions annually for 3 years in addition to daily oral calcium and vitamin D.

Postmenopausal women between the ages of 65 and 89 with a BMD T-score of -2.5 or less at the Femoral Neck (FN) (with or without evidence of a previous vertebral fracture), or a T-score of -1.5 or less with radiologic evidence of a previous vertebral fracture were studied. The primary efficacy endpoints were new vertebral fractures and hip fracture. Secondary endpoints included non-vertebral fractures, changes in BMD and changes in BTM (P1NP,  $\beta$ -CTx, and BSAP).

Treatment with Reclast was found to reduce the risk of morphometric vertebral fracture (fractures identified by measurement of vertebral height on spine radiograph) by 70% during a 3-year period as compared to PBO (3.3% in the Reclast group vs. 10.9% in the PBO group) (Figure 3-1), and reduced the risk of hip fracture by 41% (1.4% in the Reclast group vs. 2.5% in the PBO group) (Figure 3-2). Non-vertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (p<0.001 for all comparisons) compared with PBO group (Figure 3-2).

The number of fractures prevented per 100,000 patient-years (pt-yrs) of treatment with Reclast based on these findings is 2533, 1467 and 367 for morphometric vertebral fracture, any clinical fracture and hip fracture, respectively. The number of patients needed to treat (NNT) to prevent 1 fracture with 3 annual infusions was 13.2, 22.7 and 90.9 for morphometric vertebral fracture, any clinical fracture and hip fracture, respectively (Data on File).

BMD and markers of bone turnover were assessed as surrogate markers of efficacy. Reclast was associated with a significant improvement in BMD. Total hip, lumbar spine and FN BMD increased significantly by 6.0%, 6.7%, and 5.1%, respectively, compared with PBO (p<0.001 for all comparisons). All 3 biochemical markers of bone turnover decreased significantly in patients in the Reclast group as compared with those in the PBO group (p<0.0001 for all comparisons), and importantly, the mean values remained within the premenopausal reference range over the 3 year treatment period.







<sup>+</sup> mITT included all ITT patients who were evaluable for incident vertebral fractures over the period being analyzed. <sup>\*</sup>Relative fracture risk reduction (CI)



Figure 3-2 Effect of zoledronic acid treatment on the risk of hip and other clinical fractures over time – Study H2301 (ITT)

In patients with OP treated with antiresorptive agents, reduction in bone turnover can explain part of the observed fracture risk reduction. Lower levels of BTM have been associated with a lower risk of fracture in BP-treated patients. The association between changes in BTM and fracture incidence was assessed in 1132 patients who had P1NP measurements at baseline and 1 year as part of this Pivotal Fracture Trial. In this post hoc analysis, annual injections of Reclast reduced markers into the premenopausal reference range, with a significant response persisting after the third infusion. Clinical fracture risk at 3 years was lower in those with lower levels of P1NP at 1 year. Furthermore, there was no association between low P1NP levels at 1 year and increased fracture incidence (Delmas 2009).

#### 3.2 Reclast Pivotal Fracture Trial Extension up to 6 years (H2301E1)

The Reclast Pivotal Fracture Trial study was extended to 6 years, to investigate the long-term effects of Reclast in women with PMO through assessment of the surrogate marker BMD and secondarily on fracture risk reduction.

1233 women who received Reclast for 3 years in the Core study (H2301) were re-randomized to blinded treatment with Reclast or PBO for an additional 3 years (zoledronic acid up to 6 years: Z6, n=616; 3 years of zoledronic acid followed by 3 years of PBO: Z3P3, n=617). In order to retain the blind of the Core study, patients who had received PBO for 3 years during the Core study were assigned to receive Reclast in the extension study (P3Z3, n=1223). As

the pre-planned analysis of this study was designed to assess the difference between the Z6 and Z3P3 groups, and as the P3Z3 group was not a randomized study population, only the data for the two randomized treatment groups (Z6 and Z3P3) are provided below.

The primary efficacy endpoint was the percentage change in FN BMD from Year 3-6. Prespecified secondary endpoints included BMD at other sites, fractures (morphometric vertebral, hip, clinical vertebral and non-vertebral), BTM, and safety parameters.

In the Z6 group, FN BMD increased from baseline to Year 3 and was maintained up to 6 years (Black 2010 ASBMR Oral Presentation). In the group that discontinued Reclast after 3 years (Z3P3) FN BMD showed modest loss (between treatment difference 1.36%), though it remained well above the mean pretreatment BMD from Year 0 of the Core study (Figure 3-3). Similar findings were observed for total hip and lumbar spine BMD.





Values shown are for patients treated with Reclast in the Pivotal Fracture Trial who were subsequently re-randomized to the Z6 and Z3P3 groups. The FN BMD values were not significantly different at re-randomization. Year 4.5 is ITT population, year 6 is mITT population.

During the 3 years of the extension study, the mean P1NP rose slightly in both the Z3P3 (+32.5%) and Z6 (+19%) groups (Figure 3-4). Three years after discontinuation, P1NP remained below pre-treatment levels for the Z6 and Z3P3 groups. The values for most patients in both treatment groups were within the normal pre-menopausal reference range (15.1-58.6 ng/mL per Synarc technical protocol for serum P1NP, dated Mar 1, 2010). The patterns of change were similar for  $\beta$ -CTX and BSAP, but the sample sizes for these markers of bone resorption were too small to draw meaningful conclusions.



The horizontal reference lines are the lower and upper normal pre-menopausal reference limits (15.1 and 58.6 ng/mL). Min, 1<sup>st</sup> quartile, median, 3<sup>rd</sup> quartile, and max are presented in each plot.

Incident morphometric vertebral fractures have been shown to be associated with significant pain, limited activity, disability and increased risk of future fractures. During the Core study (H2301), the incidence of new morphometric vertebral fractures in the PBO group was 10.9% which was reduced to 3.3% in the Reclast treatment group. In this extension study (H2301E1), the rate of morphometric vertebral fractures was 6.2% in the patients that discontinued Reclast (Z3P3), and 3.0% in the group that continued Reclast (Z6), Z6 vs. Z3P3, p=0.035 (Figure 3-5), suggesting that while some benefit persists even after discontinuing therapy, greater benefit is achieved with continued therapy. The sample size in the extension trial was relatively small and the fracture incidence was low, therefore making it difficult to assess non-vertebral fracture outcomes.





After 3 years of annual Reclast treatment, the Z3P3 group (those who discontinued therapy for up to 3 years) maintained their mean BMD above their Core pretreatment value. Nevertheless, a significant reduction in the risk for morphometric vertebral fractures was observed in patients who continued annual treatment for 6 years as compared with those who discontinued treatment (Figure 3-5). These data demonstrate NNT of 31.3 for prevention of these fractures over the 3 year extension treatment period, representing prevention of 1067 fracture events per 100,000 pt-yrs (Data on File).

Thus, stopping treatment after 3 years of annual Reclast therapy may not be optimal for all PMO patients. To address this issue, Novartis conducted a *post-hoc* analysis to identify the predictors of new vertebral fracture risk and to determine which subgroups of patients may be most likely to benefit from continued therapy (Data on File). The most important predictors of new morphometric fracture risk in the Z3P3 group were FN or total hip T-score at H2301E1 baseline  $\leq$ -2.5 [Odds Ratio (95% Confidence Interval [CI]) = 3.3 (1.4, 8.0), p=0.008; and 4.01 (1.8, 8.9), p=0.0007, respectively], and incident morphometric vertebral fracture during the Core study (Odds Ratio 4.74 [1.3, 16.7], p=0.0156). Significant beneficial treatment effects (absolute fracture risk reduction and lowest NNT) with continued Reclast in H2301E1 were seen in these high risk subgroups. While it is acknowledged that the sample size for this analysis is small and should be interpreted with caution, the findings are consistent with the OP literature.

## 3.3 Reclast Recurrent Fracture Trial in patients with recent hip fracture (H2310)

Hip fractures are associated with increased morbidity, functional decline, and death in older adults. One source of the excess morbidity in patients with hip fractures is new osteoporotic fractures. Such fractures occur at a rate of 10.4 per 100 patients-years, which is 2.5 times the rate in age-matched persons without previous hip fracture (Colon-Emeric 2003).

Reclast was investigated to assess its impact on reducing clinical fractures in patients who had an incident low trauma hip fracture. In this trial with a median patient follow-up of 1.9 years,

the rate of any new clinical fracture was 8.6% in the Reclast group and 13.9% in the PBO group, correlating to a 35% risk reduction with Reclast (HR [95% CI] = 0.65 [0.50 to 0.84], p=0.001) (Lyles 2007) and extrapolating to the prevention of 2650 fractures per 100,000 ptyrs of treatment. The rates of new clinical vertebral fracture were 1.7% in the Reclast group and 3.8% in the PBO group (p=0.02), and the rates of new clinical non-vertebral fracture were 7.6% and 10.7%, respectively (p=0.03). There was a non-significant trend in the reduction of recurrent hip fractures (HR=0.70; p=0.18), with a new hip fracture rate of 2.0% in the Reclast group and 3.5% in the PBO group (Table 3-2).

Table 3-2	Rates of fracture in men and women with an incident hip fracture over median 1.9 years
	follow-up (H2310)

Location	Reclast (N=1065) n (%) <sup>1</sup>	Placebo (N=1062) n (%) <sup>1</sup>	Hazard Ratio (95% Cl)	p-value	Number of fractures to prevent per 100,000 pt-yrs of treatment	NNT
Any clinical fracture	92 (8.6)	139 (13.9)	0.65 (0.50–0.84)	0.001	2650	18.9
Non-vertebral fracture	79 (7.6)	107 (10.7)	0.73 (0.55–0.98)	0.03	1550	32.3
Hip fracture	23 (2.0)	33 (3.5)	0.70 (0.41–1.19)	0.18	750	66.7
Clinical vertebral fracture	21 (1.7)	39 (3.8)	0.54 (0.32–0.92)	0.02	1050	47.6

<sup>1</sup>For clinical fracture end points the number of subjects with events is provided along with the 24month Kaplan-Meier estimates of the cumulative event rate

Total hip BMD was assessed as a surrogate marker at the contralateral hip. An increase in total hip BMD was observed in the Reclast group (2.6% at 12 months, 4.7% at 24 months and 5.5% at 36 months) and declined in the PBO group by 1.0%, 0.7%, and 0.9%, respectively.

In this trial of highly co-morbid osteoporotic patients, Reclast was also found to reduce the risk of death by 28% compared to PBO (a first for an OP therapy). This observed mortality benefit was manifested after the first year of treatment, and persisted after adjustment for baseline demographic and prognostic variables. While subsequent fractures were significantly associated with death (HR 1.62, 95% CI 1.09-2.40), they only explained 8% of the survival benefit (Colon-Emeric 2009).

Although osteoporotic fractures (including vertebral fractures) have been shown to be associated with increased mortality, this significant mortality reduction was unexpected in a trial powered to show a reduction in clinical fractures. The pathway and underlying mechanism producing this death benefit remains unknown.

#### 3.4 Reclast Prevention of Bone Loss (N2312)

During the onset of estrogen deprivation due to menopause, there is a loss of bone mass resulting from increased bone resorption. Some women have significant bone loss during the perimenopausal period that may progress to osteopenia which is associated with an increased risk of fracture and continuing bone loss resulting in OP.

Reclast has been evaluated for the prevention of PMO in a 2 year study that compared a single Reclast infusion or two annual infusions with PBO (McClung 2009). 581 postmenopausal

women with low bone mass (BMD T-scores between -1.0 and -2.5) were enrolled in a two year trial where they were treated with one of 3 treatment regimens: 1) PBO, 2) Reclast at baseline only or 3) Reclast at baseline and 1 year. The objective was to assess the percent change in lumbar spine BMD at 24 months relative to baseline.

In the analysis, women were stratified into 2 groups based on the number of years from menopause (Stratum I: <5 years [n=224] or Stratum II:  $\geq$  5 years since menopause [n=357]). The results showed that Reclast given once significantly increased lumbar spine BMD relative to baseline at 2 years in both Strata (4.0% in Stratum I and by 4.8% in Stratum II). The PBO group had a decrease in lumbar spine BMD: -2.2% in Stratum I and -0.7% in Stratum II at 24 months. There was also a significant increase in hip BMD in the Reclast group while there was a loss of BMD in the PBO group (Figure 3-6).

The treatment group who received 2 annual infusions of Reclast had a significant increase in lumbar spine and hip BMD relative to PBO which was numerically greater but not significantly different from the group that received a single infusion.

## Figure 3-6 Effect of Reclast treatment on lumbar spine BMD in postmenopausal women with osteopenia



LMP = Last Menstrual Period. Stratum I <5 years from menopause; Stratum II  $\geq$  5 years from menopause (LMP). \*Reclast vs. placebo, \*Reclast (Year 1 and 2) vs. Reclast (Year 1 Only).

While no trial with BP in osteopenic patients has been designed to assess fracture end-points (due to the necessary sample size and anticipated length of study to assess the end-point), the increase in BMD with BP treatment is anticipated to reduce the known increased rate of fractures (1.8-fold increase compared with normal BMD; Siris 2001) and delay the progression to OP.

#### 4 Review of Reclast safety data

In the Reclast clinical development program for OP/osteopenia, the most common adverse events (AE) include: pyrexia, myalgia, flu-like illness, headache, and arthralgia. The majority of these symptoms occur within the first 3 days following Reclast infusion. The overall incidence of serious adverse events (SAEs) and discontinuations due to AEs in clinical trials was similar between Reclast and comparator groups as presented in the USPI. After the 3 day post-infusion period, the overall incidence of AEs was comparable to PBO. AEs observed during the clinical program are more fully described in the USPI.

In order to fully evaluate the safety profile of Reclast during the development program, Novartis prospectively incorporated an adjudication program to oversee the evaluation of events of special interest within the clinical trials program. The adjudication program was built utilizing pre-defined Medical Dictionary for Regulatory Activities (MedDRA) preferred AE terms and laboratory parameters which triggered blinded external expert review to assign "relationship" to Reclast use. The events of interest included: ocular, hypocalcemia, renal, maxillofacial, joint-related avascular necrosis and delayed union/nonunion of fractures, arrhythmia and cause of death.

Novartis routinely provides summaries of these events of interest to regulators as part of its on-going post-marketing surveillance regarding Reclast, to which Novartis is committed both in the U.S. and world-wide. To summarize briefly:

- Ocular inflammatory events: Not visually threatening, can generally be treated with topical therapy using either steroids or antibiotics. Consistent with those observed with other BP.
- Hypocalcemia: Typically transient and asymptomatic, with full recovery following supplementation of calcium.
- Renal impairment: Marginal and transient increase in serum creatinine following infusion may occur without long-term effect on renal function (Boonen 2008). Post-marketing renal reports including renal failure requiring dialysis or with a fatal outcome have been received with a low reporting rate, primarily in patients with pre-existing renal impairment, dehydration before or after the infusion, advanced age or concomitant use of nephrotoxic medications.
- Maxillofacial (includes ONJ): To be discussed in detail in Sections 4.2, 4.3 and 4.7 below.
- Joint-related avascular necrosis and delayed union/nonunion of fractures: No evidence of an increased risk was observed in the clinical trials.
- Atrial fibrillation: One trial in the development program found an imbalance in the incidence of atrial fibrillation SAEs between Reclast and PBO. No plausible mechanism and no evidence of a causal relationship between atrial fibrillation and Reclast has been established (Camm 2010).

• Cause of death: No evidence of an increased risk was observed in the clinical trials. A possible association between oral BP and esophageal cancer has been reported (Wysowski 2009) since the completion of the phase III registration program. Therefore, this event was not prospectively adjudicated. In a review of the Reclast clinical trials database, there is no evidence of an increased risk (2 reports of esophageal cancer in PBO treated patients and no reports in Reclast treated patients). Atypical subtrochanteric femur fractures: to be discussed in detail in Sections 4.4, 4.5 and 4.8 below.

#### 4.1 Bone safety

This section focuses on the long-term use of Reclast, related to bone safety, and will outline the available information as it relates to ONJ and atypical subtrochanteric femur fractures.

Treatment with first-generation BP such as etidronate raised concerns over potential mineralization defects (Jowsey 1971). Defective mineralization has not been observed in long-term clinical studies with the nitrogen-containing BP, alendronate, risedronate, and ibandronate, which do not share the same propensity for mineralization defects as etidronate. These studies also reported total absence of other qualitative abnormalities (woven bone, marrow fibrosis, or signs of cellular toxicity) in newly formed bone. Reclast is a third-generation nitrogen-containing BP displaying the highest inhibition of FPPS and greatest affinity for bone mineral to date.

Novartis prospectively assessed bone quality in a substudy of the Pivotal Fracture Trial (H2301) in which 152 patients underwent bone biopsy. Analysis of bone structure by Micro computerized tomography (CT) revealed better preservation of trabecular structure after treatment with Reclast than with PBO. Qualitative analysis revealed presence of tetracycline label in 81 of 82 biopsies from patients on Reclast and all 70 biopsies from PBO patients, indicative of continued bone remodeling. There was no evidence of marrow fibrosis, woven bone or osteomalacia after 3 years treatment with Reclast (Recker 2008).

In the Extension study (H2301E1), histomorphometry and micro CT data were available for 5 patients (3 in the Z6 group and 2 in the Z3P3 group) at the 6 year timepoint. All biopsies contained double tetracycline labeling, no evidence of osteomalacia, woven bone, cortical trabeculation or marrow fibrosis. The micro CT data revealed preservation of trabecular bone structure.

Yearly i.v. zoledronic acid 5 mg for 3 years resulted in a median 63% reduction of bone turnover with preservation of bone quality and no evidence for adynamic bone.

#### 4.2 ONJ Overview

ONJ is a dental event defined as an area of exposed bone in the maxillofacial region that does not heal within 8 weeks despite proper dental care, in a patient who has not had radiation therapy to the craniofacial region (Khosla 2007; Recknor 2011). The American Society of Bone Mineral Research (ASBMR) appointed a multidisciplinary Task Force in 2007 to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. Their report summarized the findings and recommendations of the Task Force focusing initially on ONJ in patients treated with BP. However, ONJ has since been reported in patients treated with denosumab, a RANK-ligand inhibitor that inhibits bone resorption and is also indicated for the treatment of OP. Therefore, reports of ONJ events are not limited to use in patients who have received BP therapy. Risk factors for ONJ include: periodontal disease (including gingivitis), mucositis, infectious osteomyelitis, sinusitis, dental abscess, bony tumors and metastases (Khosla 2007). Treatment with chemotherapy and corticosteroids has also been identified as risk factors for ONJ. Postmarketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (e.g. advanced breast cancer, multiple myeloma) and dental status (dental extraction, periodontal disease, local trauma including poorly fitting dentures). Many reports of ONJ, both in patients receiving i.v. BP therapy and those who have not, involve patients with signs of local infection, including osteomyelitis.

Based on review of both published and unpublished data, the reported incidence rate of ONJ in patients receiving oral BP therapy for OP appears to be very low, with estimates ranging between 1 and 10 per 100,000 patient-treatment years (Khosla 2007).

#### 4.3 Reclast clinical trial data and ONJ

In light of reports of a potential association of ONJ and BP therapy, Novartis established a formal prospective program for the evaluation of ONJ during the Reclast clinical trials program. The clinical trial program with Reclast is the only BP program for OP treatment to prospectively adjudicate for ONJ. To objectively and independently assess maxillofacial AEs and to identify possible causal relationships, an adjudication process was established. The blinded, external adjudication committee consisted of 5 independent expert dental specialists who reviewed maxillofacial AEs from all studies. The pre-specified definition of ONJ for purposes of adjudication was "exposed bone with delayed healing despite 6 weeks of appropriate medical care" (Ruggiero 2004), which predates, and is more conservative than, the definition established by the ASBMR Task Force (Khosla 2007).

A list of 60 MedDRA preferred terms was selected by the adjudication committee in order to identify potential cases of ONJ. When a potential case was identified through search of MedDRA terms on the clinical trial AEs database, the clinical site was requested to provide a standardized set of information defined by the adjudication committee. A thorough description of the event with a detailed follow-up of the patient's medical history, concurrent medical conditions, and relevant source documents was requested for review by the committee in a blinded fashion which then assessed whether each case met the specified criteria for ONJ. Cases adjudicated as "confirmed" would meet the ONJ criteria regardless of whether a duration of 6 or 8 weeks was used as the criterion.

While no reports of ONJ have been received by verbatim terms within the Reclast clinical trials program, there were 4 cases of ONJ confirmed through adjudication, two in the pivotal fracture study (one "probable" case in the Reclast group and one "possible" case in the PBO group) and two in the Reclast Extension Study (one in the Z6 and one in the P3Z3 group). All 4 cases resolved with therapy. Patient narratives for adjudicated events of ONJ are presented in the Appendix. The data represent a reporting rate of 8.8 per 100,000 pt-yrs for the phase III and IIIb trials, which is consistent with the rate of ONJ that has been reported with oral BP use in OP (Khosla 2007). The calculated number needed to harm (NNH) for ONJ is 3783 for patients who receive 3 years of Reclast therapy.

#### 4.4 Atypical subtrochanteric femur fractures overview

Atypical subtrochanteric femur fractures have recently emerged as a potential safety signal in patients on long term BP therapy. These fractures have specific radiographic features, and all major features are required to satisfy the case definition of atypical femur fracture. The major features are (Shane 2010):

- Located anywhere along the femur from just distal to the lesser trochanter to just proximal to the supracondylar flare
- Associated with no trauma or minimal trauma, as in a fall from a standing height or less
- Transverse or short oblique configuration
- Non-comminuted
- Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex.

Atypical subtrochanteric femur fractures have also been reported in osteoporotic patients who have not been treated with BP, which can confound the evaluation of an association with BP.

## 4.5 Reclast clinical trial data and "atypical" subtrochanteric femur fractures

To evaluate available data related to atypical subtrochanteric femur factures within the Reclast clinical program, a retrospective search of the AE database using the MedDRA preferred terms for hip fracture and femur fracture was conducted for all Reclast phase III and IIIb clinical trials, including those trials of OP in men and glucocorticoid-induced OP. Five reports of subtrochanteric femur fracture were received (2 on PBO and 3 on Reclast). Clinical fractures in the clinical trials program were verified based on either radiograph (X-ray), radiographic report or surgical report. The major features of atypical fractures can only be verified based on review of radiographic images; which were not available for these 5 reports. The 5 reports of subtrochanteric femur fracture thus could not be confirmed or excluded as atypical.

Novartis also commissioned a re-analysis of the Reclast Pivotal Fracture Trial (Black 2010). On interrogation of the trial database, a total of 84 hip or femur fractures were identified for assessment by a blinded external expert radiologist who reviewed all available data including radiographic reports. Of these, 5 subjects who had 6 fractures meeting the pre-specified regional criterion for fracture of the subtrochanteric femur were identified. Three were receiving Reclast (2.8 per 10,000 pt-yrs) and 2 were receiving PBO (1.9 per 10,000 pt-yrs). Although the location of these fractures was subtrochanteric, atypical features (per ASBMR criteria) could not be fully assessed in this retrospective analysis since primary radiographs were not available.

Therefore, there are no confirmed cases of atypical subtrochanteric femur fractures in the Reclast clinical trials program. As a result, a reporting rate for atypical subtrochanteric fractures cannot be determined.

#### 4.6 **Post-marketing experience**

To provide additional perspective on the potential risks and benefits of Reclast in the treatment and prevention of OP, Novartis has reviewed its post-marketing database. As of 30-Jun-2011, the worldwide patient exposure to Reclast (including Aclasta, the trade name used outside of the US) was estimated to be over 2.3 million pt-yrs.

Because AE reports in a postmarketing setting are received voluntarily from a population of uncertain size and in many cases are reported with limited information, it is not possible to reliably estimate the frequency of postmarketing events or to reliably establish a causal relationship to drug exposure.

#### 4.7 Post-marketing reports of ONJ

The published incidence of ONJ in OP patients treated with oral BP is estimated to be 1-10 per 100,000 patient treatment-years (Khosla 2007). ONJ has been reported in the Reclast postmarketing setting at a rate of 4.5/100,000 pt-yrs, which is consistent with the published rates for oral BP. The majority of the ONJ reports to date have provided limited information to confirm the diagnosis of ONJ (e.g., lack of information on the occurrence of exposed jaw bone or event duration). The risk factors for ONJ that were identified as part of the review of the Reclast case reports include preceding dental procedure, long-term exposure to steroids, poor oral hygiene, and prior use of other BP.

Novartis will continue to closely monitor ONJ through its pharmacovigilance activities.

## 4.8 Post-marketing reports of "atypical" subtrochanteric femur fractures

There have been rare post-marketing reports of subtrochanteric or diaphyseal femur fracture after Reclast therapy, as well as rare reports of "atypical" femur fracture. Due to limitations in the information provided with these post-marketing reports of "atypical" femur fracture (e.g., lack of information on the nature of trauma in association with the fractures, unavailability of X-ray films or X-ray reports or unspecified anatomic location for the reports of the "atypical" femur fracture), it is not possible to confirm whether these case reports meet the criteria for "atypical" femur fracture, as defined by ASBMR Task Force (Shane 2010). For the post-marketing reports of subtrochanteric/diaphyseal fracture or "atypical" femur fracture after Reclast therapy, underlying medical conditions (e.g. OP, Paget's disease of bone) may provide an alternative explanation for these events.

Therefore, there are no confirmed cases of "atypical" subtrochanteric femur fracture in the post-marketing experience with Reclast. Novartis will continue to closely monitor atypical subtrochanteric femur fractures through its pharmacovigilance activities.

#### 4.9 Novartis on-going safety evaluation program

Novartis is committed to the ongoing evaluation of the safety of Reclast and to providing appropriate information to prescribers to allow for its informed use. This includes the targeted adjudication program for events of special interest occurring in clinical studies, as described above, along with post-marketing surveillance to evaluate the safety of Reclast. The current Reclast USPI provides detailed information for prescribers on Contraindications, Warnings and Precautions, Adverse Reactions, and appropriate use in patient populations. Novartis is committed to continued dialogue with the FDA to ensure that the Reclast label reflects the available information for the product.

To further evaluate the long-term safety of Reclast especially with regard to rare skeletal events Novartis initiated a 5-year cohort study using health registries in the Scandinavian countries (Denmark, Norway and Sweden) to evaluate the safety of Reclast in relation to oral BP and matched, untreated population controls. The purpose of this ongoing, European Union post-approval commitment study is to further explore the incidence of specific safety-related outcomes including: cardiovascular events, stroke-related events, skeletal events, and ONJ. Denmark, Sweden and Norway were chosen for this study because they have national registries for the recording of prescribed drugs and disease diagnoses that can be cross-referenced. Implementation in these countries could cover a total potential subject population of 18 million people. A report of the 5-year information is expected in 2015.

# 5 Overall benefit/risk of Reclast in light of the questions being posed by FDA

An integrated evaluation of the benefit/ risk of Reclast is provided to support the answers to the questions posed by the FDA.

#### **Overall Benefit/Risk**

In postmenopausal OP, the evidence from clinical trials demonstrates significant reductions in the risk of hip, vertebral and other osteoporotic-related fractures with BP treatment over 3 years of therapy and continued reduction in vertebral fractures up to 6 years. In postmenopausal women with OP at high risk of fracture who were treated with Reclast for 3 years, the numbers of fracture events prevented ranged from 367 per 100,000 pt-yrs for hip fractures (which are associated with 20-25% 1 year mortality) to over 2500 morphometric vertebral fractures (which have long term consequences for functional status, morbidity and risk of higher morbidity fractures). After 3 years of treatment with Reclast, an additional 3 years of treatment prevented over 1000 morphometric vertebral fracture events per 100,000 pt-yrs when compared with patients that stopped Reclast treatment at 3 years. In a population of osteoporotic patients with recent hip fracture, the benefit of Reclast therapy was also demonstrated, correlating to the prevention of over 2500 clinical fracture events per 100,000 pt-yrs. Clinical fracture events are associated with significant increase in disability, morbidity, mortality and decreased quality of life. Importantly, a significant 28% reduction in mortality was observed in the highly co-morbid population studied in the Recurrent Fracture Trial.

In clinical trials, the safety and tolerability of Reclast has been demonstrated up to 6 years. Data from the Reclast clinical trials program and post-marketing reports suggest that the reported rate of ONJ in patients receiving Reclast is consistent with that estimated for the oral BP by the ASBMR Task Force Report: 1 to 10 per 100,000 pt-yrs. Within the clinical trials program and post-marketing data, there is no evidence for increased frequency of ONJ events with longer duration of therapy. The incidence of atypical subtrochanteric femur fractures in patients treated with Reclast for OP is not well established due to its rarity, and the limitations in the availability of the radiographic evidence that is required for unequivocal diagnosis of these events.

Additionally, the Reclast prescribing information provides information for the practitioner with regard to appropriate use in specific patient populations, based on available data and the known mechanism of the drug, including Contraindications (Section 4 of the Reclast label) and Warnings & Precautions (Section 5 of the Reclast label) including 'ONJ' and 'Atypical Subtrochanteric Diaphyseal Femoral Fractures'.

There are no controlled studies evaluating the effect of a drug holiday on the efficacy or safety of Reclast. In patients with OP treated with antiresorptive agents, reduction in bone turnover explains much of the observed fracture risk reduction. Lower levels of BTM appear to be associated with a lower risk of fracture in BP-treated patients. The association between changes in markers of bone turnover and fracture incidence has been assessed in patients who had P1NP measurements at baseline and 1 year as part of the H2301 Pivotal Fracture Trial. In a *post hoc* analysis of the Pivotal Fracture Trial, annual injections of Reclast reduced markers into the premenopausal reference range, with a significant response persisting after the third infusion with no association between low P1NP levels at 1 year and increased fracture incidence (Delmas 2009). The long-term data obtained as part of the Pivotal Fracture Trial Extension (H2301E1) suggests that there are patients with postmenopausal OP who continue to accrue benefits with Reclast therapy beyond 3 years.

In postmenopausal women with osteopenia Reclast increases and maintains BMD when it is administered every 2 years, a fundamental component for the prevention of OP and osteoporotic fractures.

#### Novartis Response to Questions Posed by FDA

- Provide an opinion and discussion of whether the efficacy and safety data support a long-term duration of use (i.e., > 3 years) for Reclast<sup>®</sup> (zoledronic acid) Injection.
- Provide an opinion and discussion of whether either restricting the duration of use or implementing a drug holiday may be beneficial for patients requiring long-term treatment.

It is Novartis' position that the overall data support the annual use of Reclast for 3 years and a positive benefit/risk for treatment with Reclast up to six years in the treatment of OP. Data in patients who remain on Reclast for up to 6 years suggest that continued treatment builds and maintains BMD better than in patients who discontinued treatment after 3 years. The second 3 years of Reclast treatment provided additional benefit specific to the occurrence of new morphometric vertebral fracture which are associated with increased risk of fractures. Advice to the practitioner regarding the duration of use provided in Section 1.6 of the Reclast label accurately reflects what is known about the product to date: *"The safety and effectiveness of Reclast for the treatment of osteoporosis is based on clinical data of three years duration. The optimal duration of use has not been determined. Patients should have the need for continued therapy re-evaluated on a periodic basis"*.

A *post hoc* analysis from Study H2301 describing the relationship of P1NP and BMD at 1 year post treatment in relation to fracture risk reduction at 3 years, in addition to *post hoc* analyses from Study H2301E1 outlining which patients may best benefit from continued therapy, have demonstrated that the use of BMD or markers of bone turnover are appropriate surrogate markers to help inform the decision to continue or discontinue therapy. This information, in addition to a clinical evaluation of other factors that may impact the risk for future osteoporotic fractures, such as medication use (e.g. glucocorticoids, proton pump

inhibitors), inactivity, and tobacco and alcohol use, will aid the decision of the practitioner to continue or interrupt Reclast therapy.

It is Novartis' position that the totality of efficacy and safety data with Reclast do not support a blanket restriction on the duration of use or the implementation of a drug holiday for longterm use. Current labeling recommends that the lower-risk population with osteopenia be treated with Reclast infusion every other year and that the higher risk osteoporotic population be treated with annual infusions of Reclast.

Novartis remains committed to ensuring that its products are used safely and effectively and welcomes the opportunity to engage in the discussion of these important topics.

### 6 Conclusions

- Current data support a positive benefit/risk for Reclast for up to 6 years in patients with osteoporosis.
- A decision to continue or interrupt Reclast therapy should be made by the health care provider and patient on a patient-specific basis with consideration of relevant clinical factors and bone mineral density or bone turnover markers
- The existing data do not support a specific limitation on the duration of use of Reclast for all osteoporosis patients.

### 7 References

Actonel<sup>®</sup> US Prescribing Information, January 2011

Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, BucciRechtweg C, Su G, Eriksen EF, Magaziner JS. (in-press 2011).Zoledronic Acid Results in Better Health Related Quality of Life Following Hip Fracture: the Horizon Recurrent Fracture Trial.. Osteoporosis International.

American Cancer Society 2008.

American Heart Association . Heart Disease and Stroke Statistics 2008

Bentler SE, Liu L, Obrizan M, Cook E, Wright K, Geweke J, Chrischilles E, Pavlik C, Wallace R, Ohsfeldt R, Jones M, Rosenthal G and Wolinsky F (2009). The Aftermath of Hip Fracture: Discharge Placement, Functional Status Change and Mortality. Am J Epidemiol. Vol 170, No10: 1290-1299

Black DM, Delmas PD, Eastell R, Reid I, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue T, Sellmeyer D, Eriksen EF and Cummings SR (2007). Once Yearly Zoledronic Acid for treatment of Postmenopausal osteoporosis. N Eng J Med; 356: 1809-1822

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, BucciRechtweg C, Cauley J, Leung PC, Boonen S, Santora A, De Papp A, and Bauer DC. (2010). Bisphosphonates and fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med; 362 : 1761-71

Black DM, et al. The Effect of 3 versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). American Society for Bone and Mineral Research (ASBMR) Annual Meeting. October 16, 2010.Oral Presentation. Boniva<sup>®</sup> US Prescribing Information, January 2011

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF and Miller PD. (2008). Renal Safety of Annual Zoledronic Acid Infusions in Osteoporotic Postmenopausal Women. Kidney International; 74: 641-648

Brown JP and Josse RG (2002). 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. JAMC 167 (10 suppl) : s1-s34

Camm JA. (2010). Review of the Cardiovascular Safety of Zoledronic Acid and Other Bisphosphonates for the Treatment of Osteoporosis. Clincial Therapuetics. Vol 32 : 426- 436

Cauley JA, Thompson DE, Ensrud KC, Scott JC and Black D (2000). Risk of Mortality Following Clinical Fractures. Osteoporos Int 11 : 556-561

Colon-Emeric C, Kuchibatla M, Pieper C, Hawkes W, Fredman L, Magaziner J, Simmerman S, Lyles KW. (2003) The Contribution of Hip Fracture to Risk of Subsequent fracture: Data From Two Longitudinal Studies. Osteoporosis Int. 14 : 879-883

Colon-Emeric C, Mesenbrink P, Lyles K, Pieper C, Boonen S, Delmas P, Eriksen E, Magaziner J. (2009). Potential mediators of the Mortality Reduction With Zoledronic Acid After Hip Fractures. JBMR 25, number 1 : 91-97

Coxon FP, Thompson K, Roelofs AJ, Hal Ebetino F and Rogers MJ (2008). Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42: 848-860

Fosamax<sup>®</sup> US Prescribing Information, January 2011

Jowsey J, Riggs BL, Kelly PJ, Hoffman DL and Bordier P. The Treatment of Osteoporosis with Disodium Ethane-1-Hydroxy-1, 1-Diphosphonate. (1971). J Lab Clin Med. Vol 78: 574-584

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggier SL, Shafer DM, Shum L, Silverman S, Van Poznak CH, Watts N, Woo SB and Shane E. (2007). Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. JBMR. Vol 22, Number 10 : 1479-1491

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JA, Pieper CF, Mautalen C, Hyldstrup L, recknor C, Nordsletten L, Moore K, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF and Boonen S. (2007). Zoledronic Acid and Clinical Fractures and Mortality after hip Fractures. N Eng J Med ; 357 : 1799-1809

McClung M, Miller P, Recknor C, Mesenbrink P, BucciRechtweg C and Benhamou CL (2009). Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics and Gynecology. Vol 114, No 5: 999-1007

National Osteoporosis Foundation 2008.

National Osteoporosis Foundation. (2010) Clinician's guide to Prevention and Treatment of Osteoporosis.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. (2001). Osteoporosis Prevention, Diagnosis and Therapy. JAMA, Vol 285, No 6 : 785-795

Recker RR, Delmas P, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J and Eriksen EF. (2008). JBMR. Vol 23, Number 1 : 6- 16

Recknor C. (2011). Zoledronic Acid for Prevention and Treatment of Osteoporosis. Expert Opin.Pharmacother. 12 (5) : 807-815

Reclast<sup>®</sup> US Prescribing Information March 2011

Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff S. (2004). Osteonecrosis of the Jaws Associated with the Use of Bisphosphonates: A Review of 63 Cases. J Oral Maxillofac Surg 62: 527-534

Russell GG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley P, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB and Ebetino FH (2007). Bisphosphonates. An Update on Mechanisms of Action and How These Relate to Clinical Efficay. Ann.N.Y.Acad.Sci. 1117 : 209-257

Russell G, Watts NB, Ebetino FH, Rogers MJ. (2008). Mechanisms of Action of Bisphophonates: Similarities and Differences and Their Potential Influence on Clinical Efficay.Osteop Int, 19 : 733-759

Saag K, Lindsay R, Kriegman A, Beamaer E, Zhou W. (2007). A Single Zoledronic Acid infusion Reduces Bone Resorption Markers More Rapidly Than Weekly Oral Alendronate. In Post-menopausal Women with Low Bone Mineral Density. Bone 40 : 1238-1243.

Shane E, Burr D, Ebeling P, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney, R, Ng A, Nieves J, O'Keefe R, Papapoulos S, TetSen H, VanderMeulen MC, Weinstein R and Whyte M. (2010). Atypical Subtrochanteric and Diaphyseal Femoral fractures : Report of a Task Force of the American Society for Bone and Mineral Research. JBMR, Vol 25, No 11:2267-2294

Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC and Sherwood LM (2001). Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. JAMA. Vol 286, No 22 : 2815-2822

Thompson K, Rogers MJ, Coxon FP and Crockett JC (2006) Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of vesicles after Fluid-Phase Endocytosis. Molecular Pharmacology. Vol 69, No.5 : 1624-1632

Wysocki DK (2010). Reports of Oesophageal Cancer With Oral Bisphosphonate Use. N Eng J Med 360 : 89-90

### **APPENDICES**

#### Narratives of Adjudicated ONJ cases from Reclast Clinical Trials

#### Reclast pivotal fracture trial (H2301)

**Placebo treatment group:** This patient (0601-00019) in the placebo group presented 6 months after the 3rd infusion with a lesion in the region of the left maxilla that was inflamed and painful to palpation. Osteitis was diagnosed without any clinical evidence of a soft tissue infection. Two debridements on the infected area and antibiotic therapy were performed as treatment for the condition. The time to resolution was approximately 8 months. This case was adjudicated a "possible" case of ONJ.

**Reclast treatment group:** This patient (0311-00020), a 70-year-old insulin-dependent diabetic in the Reclast group who had never had regular dental care. She presented with an abscess in the residual root of a previous extraction 5 months after her 2<sup>nd</sup> infusion. Given her poor dental hygiene and long-standing diabetes, this patient was at high risk for delayed healing and other complications. An additional 12 extractions and curettage were performed. Within a week, the patient became extremely ill and was diagnosed with a periodontal infection. She refused hospitalization. The infection subsequently spread to the mandibular bone, resulting in osteomyelitis. The osteomyelitis resulted in necrosis of part of the mandible, which was confirmed radiographically. The patient was subsequently treated with antibiotics. Resolution of the infection with full healing was confirmed by X-ray. This case was adjudicated a "probable" case of ONJ.

#### **Reclast pivotal fracture trial extension (H2301E1)**

The extension study had two adjudicated reports of ONJ, one in the Z6 group and the other in the P3Z3 group (patients received placebo for the first 3 years and Reclast during the extension study). The narratives for these cases are presented in below. Both patients made a complete recovery following treatment with antibiotics and dental care.

The first patient (0736-00120), a 77-year-old Asian female in the Z6 group, presented 6 months after her 5<sup>th</sup> Reclast infusion. She was a smoker with a medical history of poor dental hygiene, periodontal disease, and loss of a tooth. Her dental visits occurred on an emergency basis only. She presented with mandibular pain, swelling, pus discharge from the alveolar ridge and numbness of the lower lip. The patient made a complete recovery following treatment with antibiotics, wound debridement and sequesterectomy.

The second patient (0324-00062), a 76-year-old Caucasian female in the P3Z3 group presented 10 months after her 2<sup>nd</sup> infusion. She had a medical history of alcohol use, dental caries, and periodontal disease. The patient presented with mild tooth infection due to an infected tooth socket. She made a complete recovery following treatment with antibiotics and wound debridement.

## $\mathcal{U}$ novartis

Reclast<sup>®</sup> US Prescribing Information

 Animotycosidis. Way lower serum calcum for prolonged periods
 (7.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1)
 (2.1) Wanning Sub OF RECAUTION:
 The Second Secon FULL PRESCRIBING INFORMATION: CONTENTS\* 1. INDICATIONS AND USAGE 1.1 Transmert doepocrosis in Postmeropausal Women 1.2 Prevention of Ostopocosis in Astimeropausal Women 1.3 Ostopocrosis in Men 1.4 Glococortexid-Induced Ostopocolis 1.4 Glococortexid-Induced Ostopocolis Including given incluses over no less than 15 minutes:
 Treatment of postmerropausal osteoporosis (2:1); treatment to increase bore mass in men with sofetoporosis (2:3); treatment and prevention of glucoconticolid-induced osteoporosis (2:4): 5 mg once prevention of glucoconticolid-induced osteoporosis (2:4): 5 mg once See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient1abeling To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Reclast<sup>e</sup> (zoledronic acid) Injection Initial U.S. Approval: 2001 wmosl common adverse reactions (>-10)
 wadota arthruiga, pain in estromity (>1,0%) were pirexia, myalgia,
 wadota arthruiga, pain in estromity (6,1). Other clinicitally important
 versor reactions were in-luke illness, navsea, vomiting, dearrhea (6,2),
 deye inflammation (6,1). mg in a 100 mL ready-to-Infuse solution (3) IGHLIGHTS OF PRESCRIBING INFORMATION hose highlights do not include all the information needed to locast SAFELY AND EFFECTIVELY. See full prescribing stormation for RECLAST. A year of the provided of the Severe incapacitating bone, joint, and/or muscle pain may occur. Withhold future doses of Reclast if severe symptoms occur (5.7) 1.5 Paget's Disease of Bone 1.6 Important Limitations of Use DOSAGE FORMS AND STRENGTHS---avenously over no less than 15 minutes: Revised: 03/2011 01/2011 01/2011 03/2011 USe 
 FUL PRESCRIBING INFORMATION
 I

 1
 Transmitol Obsponse in Performengausal Women Rectast indicated for tradues for discognosis in poteneorgana moren. In programming and women women to discognosis in poteneorgana moren. In programming and the product of the product of the product of tradues for particle and non-write all discognosis. In the objective of tradue shows the product of the product instructure spee characteristic block of 4.1.
 Instrume the product of the product of the product in fordard for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the pro-result indicated for the product of the product of the result indicated for the product of the product of the result indicated for the product of the product of the product of the result indicated for the product of the product of the product of the result indicated for the product of the product of the product of the result indicated for the product of the product of the product of the result indicated for the product of the product of the product of the result indicated for the product of the product of the 10 OCED00.000
 10 OCED00.000
 12 OCED00.000
 14 OCED00
 14 OCED00.000
 14 OCED00.000
 14 OCED00
 7 Digus Microsoftas 7 Anning/positis 7 Anning/positis 7 Non Directos 7 Nong Frincip Conditions 8 Non-Top Conditions 8 Norman State 8 Friedric Unit 8 Schwarts (Norman) \* Sections or subsections omitted from the full prescribing information are not listed 2 DISAGE AND JOHNISTRATION
 2 DISAGE AND JOHNISTRATION
 2 DISAGE AND JOHNISTRATION
 2 DISAGONGSI IN Continengausal Women
 2 Otsepongsi In Positranengausal Women
 2 Otsepongsi Information
 4 Trahemat and Prevention of Cluscopricts
 5 Trahemat and Prevention of Cluscopricts
 4 Trahemat and Prevention of Cluscopricts
 5 Trahemat and Prevention of Cluscopricts
 5 Trahemat and Prevention
 6 Disagonsity 6 ADVERSE REACTIONS 6.1 Clinical Studies Experience 6.2 Post-Marketing Experience DOSAGE FORMS AND STRENGTHS

 
 Hyper Restart
 Restart

 Intermediation fractions incurring microartes of units and analysed mm, and analysis decisions have been reported (see Not-Meddad)
 Section 2018

 Section 2018
 Section 2018
 Section 2018

 Section 2.6 Method of Administration
 2.6 The Gradet Method from multitols will be instant in 5 minutes given over a
 constant function rate.
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the former of the IA
 The List Instruction of the IA
 The List Instruction of the IA
 The IA
 The List Instruction of the IA
 The
 The IA
 The IA
 The IA Transhmirt of Dielegonstein Programsspanal Womm The recommended regiment is a right proteins rock as way offen intravenously over roless that is invited is for oddapodosity traitment and to recurs the rock of hypocalential galancia much as excepted of telest supplemented with ecclucion and vitamin 0 field any index 6 scot officient Postmoreasa women requires an excepted of telest (200 mg accium and 900-1000 uVitamin 0 data).
 Zherrentian of the rock of the 2.5 Taulanini d'Aqué e Davas el Bave Taut commonde das à la primora in testadari line musi no bé reste bar i l'omotes given over a constant l'indexi indexi ani Torico ha mise el trovaria d'anti anti anti anti anti anti Torico ha mise el trovaria l'anti anti anti anti anti anti sondir neues 150 mg elementa la cidura d'al y in debid dassi (750 mg hori mes and av 500 mg three mises a sign and 6001 d'antini to diago particularity in termes to conseq elevana d'antinestration valamino todigo particularity in termes to conseq elevana d'antinestration Al patients bandari la recellarito in the functionaria (2010) Al patients bandari la recellarito in termes d'antinestration al popotential por termestration neues (2011) CONTRAINDICATIONS
 A CONTRAINDICATIONS
 An Hypocalcentia
 See Warnings and Precautions (5.2)
 Conformic Acid or Any Components of
 A Phypersentitivity to Zoledronic Acid or Any Components of
 Recisal 2.4 Trustment and Provention of Oliveccorticolo-Induced The incorporate of the provide one can a part phen intervolved and the intervolved one can be and intervolved and the canon of the dark here and supported the case in a red start of the dark here and supported the case in a red start of the dark here and sufficience is a weaking at a weaking the dark in the dark sufficience is a weaking at a terminated and a support to the dark sufficience is a weaking at a terminated and a support of the dark in the Patents must be appropriately hydrated prior to annivistration of Rectard (see Normby and Prevantions) C31. The IX initiation should be followed by N1 DmL normal safine frush of the Hornweak Rectargories and the second prior balance administration may reduce the includered of actue-plane studied symploms is recommended A S m dore of Rectard contractive initiation in the contraction of the contractive of the c practice Ref-transmitter of Paper's Disease After a single transmitter Reduction Paper's disease an enforded semission protoid (operative Specific to Areabrend table and the Specific Constraints and the Constraints and the Constraints and Specific Paper Specific Constraints and the Constraints and and Folgo and Constraints and Specific Constraints and the Paper Specific Constraints and the Constraints and the Constraints who is labeled constraints and of their serum Radine prospecifics who is labeled to the Specific Constraints and the Constraints and the Constraints and Constraints and Constraints and the Constraints and C 1.6 The bas has 2 DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate mathematics and discoloration prior to administration, whenever solution and Important Limitations of Use Safely and arrectiveness of Radsal for the treatment of ostroporosis is as of clinical related for the years duration. The optimal duration of use of clinical relation to the apartonic on theory should be the provided of the continued therapy re-evaluated on a periodic basis. S. S. Reval haptened in a under a seried is a under a under a seried by a ser isment, on an Individual basis.

 
 Instituted of Decomposite Independence

 Transitional of Decomposite Independence

 Transitional of Decomposite Independence

 Transitional of Decomposite Independence

 Section 2016

 Section 2016

 Decomposite Independence

 Section 2016

 Section 2017

 Section 2017

 Image: Second adverse reaction raits observed in the citical risks of a duty cannot be directly compared to take in the citical risks of another drug and may not infect the raits observed in practice. 5.8 Patients with Asthma White not observed in clinical trials with Redast, there have been reports of troorchoosystiction in aspirin-sensitive patients receiving bisphosphonates. Use Redast with caution in aspirin-sensitive patients ADVERSE REACTIONS Clinical Studies Experies cause clinical trials are conduc

Syndhomes, a cockon of small indexing much as architectly insuld address insets (biophysical and magnetium) is highly incommended for these synchronizations and magnetium) is highly incommended for these synchronization is the intermediate and the intermediate of the proper advectory. An electronic and advectory is a significant risks of processes, and environment of the intermediate of the intermediate of processes and environment of the intermediate of the intermediate of processes and environment of the intermediate of the explorementation in resulting earth results and before and applementation in resulting earth results and before and applementation is maintaining attribution and the importance of advectory and advectory in the importance of the processing and advectory. A average flexibution (5), and restle processing and advector (7).

E. Programmer 
 Experiment 
 Experimpleter 
 Experimpleter 
 Experiment 
 Experiment 

ContransionCranue
 ContransionCranue

16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

Course Adverses Funds Case of UtsavetSectorial Score and the order of the adverses have a construction of the order of the order of the order to the sector of the order of the order of the order of the Prevention of School Score of the School School Score Prevention of School School Score of the School School School Prevention of School A MAY A Provinsion A MAY A Provinsion at other converse of table disclosure the science addressmetry the converse of the 3 May a State II. So Converse of the 3 May 1 May and 2 May 2 May 1 diverse even in the sciencific science of a state if clinical of science results the sciencific science of a state if clinical diverse even in the sciencific science of science of the 3 May 1 May 1 diverse even in the sciencific science of science of the 3 May 1 diverse even in the science of the 3 May 1 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 May 1 diverse even in the science of the 3 May 1 diverse even in the 3 May 1 diverse even in the 3 May 1 diverse even in the science of the 3 May 1 diverse even in the 3 May 1 diverse ev Laboratory Findings In Staty / Inverse with poster-upuausi orthoprosis, approximately 0.7% of patients has orable endanced service and the service physical beneficial and instatution. In Staty 2: Solverways we are physical beneficial wave observed in Staty 2: Solverways wave observed in Staty 2: Solverw Actor Phase Reaction The eight and semptions of a rail in prior insufation occurred in Stary 1 The eight and semptions of a rail in prior insufation occurred in Stary 1 Glowlog Reacta Industrin Toduling Terrer (1984), might apply and the semptions occurred within the first 3 days Eldowing the table of the set and usually research within 5 days of constal and enables on a distance of the set and the second within 5 days of constal and enables of the set of the second within 5 days of constal and enables of the Insufation and the top 15 r 4.4 and the second within 5 days of constal and enables of the Insufation and the top 15 r 4.4 and the second second and the second and the second second second second and the second second second and the second second second and the second second second second second second second second second and the second and the second and the second Musculoriketeal Pan Dordere au Prixula Influenza-like Ilifuenza Chille C Atrial Fibrillation In the postmenopau adverse events of al Read Impairment Traitment with the service busy costocoles, including predictoris codd, his been associated with real impairment multified as addression in read humbori, a just read and the costocoles and the costocoles and predicts in the distribution or costocoles and the costocoles predicts in the costocole and addression of the costocoles and the predicts in the costocole costocoles and the costocoles and the costocoles and the costocole costocoles and the costocoles and addression of the costocole costocoles and the costocoles and decising and the notice cost and maintening costocoles and the costocoles addression in the costocoles costocoles and the costocoles and the costocoles and the costocoles of the costocoles of the costocoles predicts in the costocoles of the costocoles of the costocoles predicts in the costocoles of the costocoles and the costocoles predicts in the costocoles of the costocoles and the costocoles to extend to be costocoles of the costocoles and the costocoles the costocoles and the costocoles of the costocoles of the costocoles to extend to the costocoles of the costocoles and the costocoles to extend to the costocoles of the costocoles and the costocoles to extend to the costocoles of the costocoles of the costocoles to extend to the costocoles of the costocoles of the costocoles to extend to extend the costocoles of the costocoles of the costocoles to extend to extend the costocoles of the cos ano Adm 17.9 5.4 5.4 5.3 4.6 2.0 1.3 0.4 4.6 2.7 2.9 4.2 1.0 1.3 1.0 1.7 3.1 1.2 1.2 5.3 5.3 0.5 0.5 1.8 
 System Organ Class
 (m.<sup>2</sup>09)
 (m.<sup>2</sup>10)
 (m.<sup>2</sup>20)
 (m.<sup>2</sup>20)

 Normal and nulfification formore
 1.6
 0.1
 (m.<sup>2</sup>20)
 0.6
 0.0

 Normal and nulfification formore
 1.6
 0.1
 0.6
 0.0
 1.4

 Normal and nulfification formore
 1.6
 0.1
 1.1
 1.5
 0.1
 1.1

 Normal and Competence
 1.7
 1.0
 1.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 0.5
 4) a submittation and quality at Myolin 1 (2 in ~ 61), and (3) planeting year at a continuation and quality at Myolin 1 (2 in ~ 61), and (3) planeting year at a continuation and work of the second second second second works in creaters 432-000 (2) grant second second second second second year and the second second second second second second second (1) Residual candidational second year (3) wear a second second second (1) Residual candidational (1) (1) (1). All here excludes a second second in adversible and glasses (9) were hown in (2 is 4%) and (3) planets who readers that and a second second second year (3) were also as a weather them is a single above the maximum second second in adversible and glasses that the second second year (3), 27.4, and 3.3% are been included planets than planets in an adversion in (3) a for cond second second second second second year (3) and (3). The form is a single second year (3) and ( Adverse Reactions Occurring  $\ln \ge 2\%$  of Patlents with Osteopenia and More Frequently than in Placebo-Treated Patients 
 Placeds
 Systems watch process watch years
 Systems watch years

 years
 years
 Systems by subsports in in years
 Systems by subsports in years

 10
 11.4
 P31
 Systems by subsports in years
 Systems by subsports in years

 10
 10
 Systems by subsports in years
 Systems by subsports in years

 10
 10
 Systems by subsports in years
 Systems by subsports in years

 10
 10
 Systems by subsports in years
 Systems by subsports in years

 11
 10
 Systems by subsports in years
 Systems by subsports in years
 Systems by subsports in years

 12
 2.5
 Systems by subsports in years
 Systems by subsports in years
 Systems by subsports in years
 Systems by subsports in years

 11
 10
 10
 Systems by subsports in years
 Systems by subsports in years
 Systems by subsports in years

 12
 2.5
 In years
 Systems by subsports in years
 Systems by subsports in years

 13
 10
 F
 Systems by subsports in years
 Systems by subsports in years

 14
 15
 Systems by subsport in years C-casting experiments
 C-casting experiments
 C-casting experiments
 C-casting experiment
 C-casting experiment
 C-casting experiment
 C-combined macrosofterial path and muscilositelial links tain as
 C-combined macrosofterial path and muscilositelial links tain as
 C-combined macrosofterial path and muscilositelial links tain as
 C-casting experiment
 C-casting experimating experiment
 C-casting experiment
 C-casting experime 
 Table 23 Adverse Released rockuring in 2-25% (Mex with Outpopped and Mex Forgung in 11.

 Outpopped and Mex Forgung in 11.

 Outpopped and Mex Forgung in 11.

 Outpop in 11.

 Patients than the Active Control Transition Patients and explores in the patients and the patient and the patients and the patient and the patients an The safety of Rescards in mark the subsported a scorebox de secondary The safety of Rescards in mark the subsported as scorebox de secondary De hypopolations was assessed in two year microbiolitic indications Leader and the safety of the subsport of the subsport of the subsport the safety of Rescards and the subsport of the subspor Diaconstructed induced of proposed in the second of t Parel 10 binese of Bene of Series (Series 1) bines bine comparison in the Backford and the Series (Series 1) binese of Backford 1 Laboratory Finding:
 There were no patients who had brahment emergent serum raidum
 the Sealewid S. migdle.
 There were no locations at the Intustion site.
 There were no locations at the Intustion site.
 Celefonerowski of the Jaw
 and Prezultare (5.4).
 and Prezultare (5.4). System Organ Class Infections and Infestations Influenza Abrial Fibriliation The Incidence of atrial inbiliation adverse events was 0.7%, (2.01416) in the Resident group compared to be adverse events in the addres control group. All subjects thad a prior history of adra inbilation and no cases were adjudicated as service adverse events. One patient had atrial flutter in the active control group. Table 4. Adverse Reactions Reported In at Least 2% of Pager's Patients Receiving Reclast (Single 5 mg IV Infusion) or Risedronate (Oral 30 mg Daily for 2 Months) Over a 6-Month Follow-Up Period Repail Impairment Renail function measured prior to dosing and at the end of the 12 month study was compruted in the Recast and active control groups [see Warnings and Precautions (5.3)]. Osteonecrosis of the Jaw In this trial there were no cases of osteonecrosis of the Jaw [see Warnings and Precautions (5, 4]. Acute Phase Reaction Redait was associated with signs and symptoms of a transient acute phase reaction that was similar to that seen in the Reclast postmenopausal osteoporosis clinical trial. 5 mg IV Reclast % (N = 177) 7 30 mg/day x 2 Months risedronate % (N = 172) ŝ 
 Miszbelina and Adrittion Disorders
 1

 Arroratik
 2

 Baspiratory
 2

 Durines
 9

 Adominal Discretion
 2

 Adominal Discretion
 3

 Arbiticities and Standower Bison
 3

 Adominal Discretion
 3

 Arbiticities and Standower Bison
 4

 Aare : been

 Generations of the Jam
 Control operation of the Jam
 C Leverage Printing
 Leverage Printing
 Leverage Printing
 Leverage Printing
 Leverage Printing
 Leverage Printing
 Leverage
 Hyperdicating
 Hyperdication
 Hyperdi cases of hypotension in patients with underlying risk factors have reported. and Bone Disorders Disorders e Conditions N - 4 N 0 = NNN-4000 -

2078648 US

 1
 Construction of the stand sector of the stan

10 Pour de la construcción de la vente construction de la vente construcción de la vente de 9.6 Real Paperment Result shade of back on patients with keep ir read impairment results of earliest 4.5 m. Non-patient back of except a clinical patients with a realistic desarrate of 4.5 m. Non-patient and the state of the state of the state of the state and the state of the state of the state of the state and the state of the state heating a state of the state of the state of the state heating as the state of the state of the state of the heating as the state of the state of the state of the heating as the state of the state of the state of the heating as the state of the state of the state of the state heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the state of the state of the state of the heating as the state of the heating as the state of the state of the state of the state of the heating as the state of the heating as the state of the state 12 CLURCH, PRAMACEDODY 21 Mechanism and Experimenty in their list as inhibits of enclastic assignments and an experimental and an experiment of enclastic assignment of support and an experiment of the spectra action of support and an experiment assignment and an experiment and action between the annual and an experiment and an experiment and action and an experiment of actions of assistance and an experiment and an experiment of actions of assistance and an experiment of a status of assistance and an experiment of a status of a status and a status of a field at teatment of a maximal down experiments. In the first of field teatment of a maximal down experiments and the first of field teatment of a maximal down experiments. I) Operational and the set of E.5 Generation and a constraint of the constr Commonly particular bandhard particular dynamic land and p 11 DESCRIPTION Receipt Constant subdomin and a bisphophome and which is an ambioit of escapation bare receiption. Laddomic and is designated ambioito of escapation and an and a subdomination of the ambioity and a data structural terminal in add monohyale at and its discutural terminal in: Hepatic Impairment si is not metabolited in the liver, to clinical data are available for r Reclast in patients with hepatic impairment PO3H2 OH-H20 187 Dispansability of the particular strength of the part of th Signation by years. Marchine has pursuancealized and a solution of an indexide by rurse index the has pursuancealized and a solution of an index by rurse index the pursuancealized and a solution of a soluti 11 Charlogenetic Allogenetic Impairment of Fertility 12 Charlogenetic Studied (Fertility Charlos Ch Address is and across the set of the address of the bit of proceeding on the address is and process the address of the address of the address both meta-address increasing be history to find a set of the address address handless and completion the and of the inclusion (process - SD in the inclusions and completion the and of the inclusion (process - SD (process)) and process and completion the address of the inclusion (process - SD (process)). The process of the inclusion (process) and process (process) and process and process of the inclusion of the inclusion (process) and process and process of the inclusion of the inclusion (process) and process of the inclusion of the inclusion of the inclusion (process) and process of the inclusion of the inclusion of the inclusion (process) and process of the inclusion of 4) Styler, and a set of each of back in which if Gargen is if mb 2. Defense, and does not back in which if Gargen is if mb 2. Defense, and does not compare backwards which is many marker, a YAN if backwards and an an an analysis of the set of the restriction of the set of Within and propedide of Pipel to date pri Pipel yay sevaluated in patients (aborest a range) run Si 7 to 12 destinasi al patients universite. Tradment with a 5-m annual does of factor to does to severe the tradment with a 5-m annual does of the antipotential (5-k) reported in b-CTL 4-25% velocition in 55% and 5 TK reduction in F1W over 35m months. There was no progressive induction of bore harrower markers with repeated annual doesing. Special Populations Performance in the second secon microindeus assay. Impairment of Fartilly: Fernate rais were given daily subcutaneous does of vice/proin-action 40 01, 0.03, or 0.01 mayba bagirning 15 days before mating and continuing through gestatera. Effects observed in the high-dose group (equivalent th human systemic exposure following a high-dose group (equivalent the human systemic exposure following a 112. Alterna i harmanelogy
 112. Alterna i harmanelogy
 113. Alterna i harmanelogy
 114. Status i harmanelogy
 11 Sing hirtawasi doe, based on an ALC compution) included inhibitor of on-baba and a diserase in the number of preparating. Extends observed in both the mid-doe group and high-does group (0.3 to 1 limes human systemic exposure following a 5 mg inclusions does based on an ALC competion included an increase in the mismittance tosts and a decrease in the number of implinizations and live lifeties. Effect on Verlebral Factures Reclast significantly decreased the incidence of new vertebral fractures at one, two, and three years as shown in fable 5.

 The second second base of The reaction is worked in buck may be here years are completed (condition memory standing and condition of the standing of th A least one new vertebral (rachure (0-1 year) A least one new vertebral frachure (0-2 years) - A least one new vertebral frachure (0-2 years) Table 5. Proportion of Patlents with New Morphometric Vertebral Fractures 3.3 22 (%) 15 10.9 7.7 3.7 Placebo (%) Acception Production non-service in Francisco and Infractions Infraction and Infractions Infraction (1, 1, 1), (2, Energy and a low where of parently parently and the parent of parently parently and the parent of parently parently and the parent of parently Error en Back Marrer (2000) (1900)
 Province in Character (2001) (1900)
 Province in Character (2001)
 Province in Character (2001 Trachan an adversariable in SU(a) 2 a noncember 2008 blob, process-centred and instructional advectance of 27.27 me and severe approx 50.5 (years) have a specific 42.5 (). Excernation of proposition approx 50.5 (years) have a specific 42.5 (). To the specific because and the specific 42.5 (). To the specific 42.5 (). The specific because and years in the specific 42.5 (). The specific 42.5 (). The specific because and years in the specific 42.5 (). The specific 42.5 (). The specific because and years in the specific 42.5 (). The specific 42.5 (). The specific because and years in the specific 42.5 (). The specific 42.5 (). The specific because and years in the specific 42.5 (). The specific 4 Outcome Any clinical 92 (8.6) fracture<sup>(1)</sup> Clinical 21 (1.7) vertebral tracture<sup>(2)</sup> "p-value <0.05, "p-value <0.005 Teenring the based on Kaplan-Melle estimates at 24 months PEccloding finger, avaid back about tees Preciding clinical thoracic and clinical lumbar vertebral factores Part Transmitter Comparison of Table Science at Key Constraint Vision Comparison of Table Science at Key Constraint Vision Comparison of Table Science Comparison Comparison

jure 2. Therapeutic Response/Serum Alkaline Phosphatase (SAP) Normalization Over Time Therapeutic Response Over Time Serum Alkaline Phosphatase (SAP) Normalization Over Time Tracky of one invitation of Simp Restarts is call daily doces in 30 mg contails of Zimolins was domesticate in the dischall of degrad this anatomics, double blind thats. The maps age of spatients was TO kinety have been percent (13% of patients were significantly and the spatial spatial spatial spatial spatial control of the spatial spatial spatial spatial spatial control spatial spatial spatial spatial spatial spatial control spatial spatial spatial spatial spatial control spatial spatial spatial spatial spatial control spatial on Bare Money I Decky (2002) 30 Caterians Laboration Resist demonstrated a significant creases in Lamba spike 6MD compared to be achieve control year (Reads 4, 1%, actice control 2, 7%) with a site harmen cost 1, 4% (policity). In the GDD prevention supportation, commonized a significant man increase in Limitant spike BMD commonized as a spiket mana increase in CML and the CML commonized as a spiket and CML and CML and the CML commonized as a spiket and CML and CML and the CML commonized as a spiket and CML and CML and the CML and the CML and CML and CML and CML and the CML and the commonized as a spiket and CML and CML and the CML and the commonized as a spiket and CML and the CML and the CML and the commonized as a spiket and CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the commonized as a spiket and the CML and the CML and the CML and the CML and the commonized as a spiket and the CML freatment of Paget's Disease of Sone was studied in mate and female patients with moderate to severe desease of bone, dofned as server alkate phosphalase level at ece the opper limit of the age specific normal reference range of study entry. Diagnosk was confirmed by radiographic a consistenzionale data terre ban havis strende ha (Sek (16):176) Est este de plands activers de response as compare les partes de plands activers de response terre de la conservation est este de la conservative de la conservative de la conservative este de la conservative de la c als Reclass demonstrated a superior and more rapid th expedidic compared within readonation and returned more patients to rives of bothe timingers evidenced by belochninical markets of risky securin CEAT (cross-linked C-telcopoptides of type 1 pilon sterum CEAT (cross-linked C-telcopoptides of type 1 and urine rs: CEA). The provide starting of protecting all proportional starting of the protecting of the protecting and starting of the protecting and starting of the protecting and starting and the protecting and starting and the protecting and starting and and the protecting and anu graduments war adultiered from 72 patients (72 m the Berjahl gradu pati 11 m har adio consoli fautiment gradu Alfondt with na minutal solar of fautimes (2004) na minutal solar of fautimes (2004) na minutal adio of fautimes (2004) na minutal fautimes ( tment and Prevention of Glucocorticold-Induced Time (Days) <u>985322</u> B Reducte Rised onele This is the period of the concentration applies easily anter a refer to concentration of the Vegenomental transfer incomparity tabular (Normal) testad and testavelia transfer incomparity and tabular (Normal) response made on End comparity in comparity of the number response made on End comparity in comparity of the number response made on End comparity in a comparity of the number strands i under incomparity and end of the number of the BNA vectories, there incomparity in a comparity of the number strands incomparity in a comparity of the number of the BNA vectories, there incomparity is a comparity of the BNA vectories, there incomparity is a comparity of the and incomparity is a comparity of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the enderstatic incomparity of the number of the number of the number of the enderstatic incomparity of the number Seret and occusionally incapacitating bore, faint action muscle path mare been interventivy spectre in patients basis basis pathogenerates, neurospectratic consider withouting our beautist transmit mare any province intervention of the second transmit second patients based with high or grain plain should be evaluated to net out allowed instance. On the day of trastment the patient should east and drink normally, which includes drinking at least 2 glasses of fluid such as water within a few neurs prior to the infusion, as directed by their doctor, before receiving Recisit Information for Patients Patients stoud be made a ware that Rectast contains the same active ingreetent (precision acid) found in Zomes<sup>4</sup>, and that patients being traited with Zomela should not be traited with Rectast. 17 PATIENT COUNSELING INFORMATION 16 NOW SUPPLIED/STORAGE AND HANDLING Each bottle contains 5 mg/100 mL NDC 0078-0435-61 Bone histology was evaluated in 7 pattents with Paget's disease 6 months after being trated with Redast 5 mg. Bone biopsy results showed bone of normal quality with ne evdence of impaired bone remodeling and no evdence of mineralization defect. Partice should be ware of the more commonly exceeded to the refet of energy Parties may exceede one or any set of energy and particle should be prepared and participation of the The system based in this strength cardinal strength and by the particle covers also calcium in obtained in the same and a system based on the system of the same and the strength of the same strength and the same strength and strength and strength of the same strength and a same strength and strength and strength of the same strength and strength and strength and strength of the same strength and strength and the same strength and a strength and a same strength and the same strength of the same strength and the same Secre being given Redast, pattents should tell their doctor if they have Morrey problems and what metcations they are baking Recussi should not be given in the pattents by segnant, or glass to become pregnant, or if she is breast-feeding [see Warnings and Procautions pregnant. See FDA-Approved Patient Labeling. Storage Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) (see USP Controlled Room Temperature). If rehigerated, allow the refrigerated solution to reach room temperature before administration. educe the incidence of these symptoms. "Inscians stoud inform their patients that there have been reports of insistering pain nation a non-healing size at the houth of year primarily noaltents theated with bioposphoralastic other. Interess, it they syndemice these symptoms, they should inform their physician or entist. sandling After opening the solution, it is stable for 24 hours at 2°C–8°C 36°F -46°F). royacitic response to Redisti was similar across demographic and s-serving young oscinativity percess year, provide bibliosphores of disease serving ALE Goothes. The percentage of Redisal-patients with a balanced transport response was 37% and 25%, patients with a balanced transport response was 37% and 25%, patients with a balanced transport response to the response of the balanced biblio 25% and 7.4% is spectrately to the results a supervise subgroups of insectional to related patients. Law calcium receipt in your folod (Typocatesma).
 Law calcium receipt in your folod (Typocatesma).
 Law calcium receipt y 2 Severa kidner prablens,
 Severa kidner prablens,
 Severa kidner problems,
 Severa kidner problems i lighter tryou:
 e alexa'r tware kidner problems
 e alexa'r tware kidner problems
 cord have accult water priv 3. Severa jaw bone problems (osteonecrosis).
 Severa jaw bone problems (osteonecrosis).
 Severa jaw bone problems man "tappen when you take 1. Petask flow docum rany tappen when you base your you shall rebask." You docum rany tell you to see your dentisa before you and Rebask. It's induportant for you's practice good mouth care during treatment with Reclast. Severe kidney problems
 Severe jaw bone problems (osteonecrosis)
 Bone, joint or muscle pain
 Unusual thigh bone fractures What is the most important information I should know about Reclast? You should not receive Reclast if you are already receiving Zometa. Both Reclast and Zometa contain zoledronic acid. Read the Medication Guide that comes with Reclast before you start taking it and seach time you get a reful. Three may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk to your doctor If you have any unctions about Bechart 4. Unusual thigh bone fractures. Some people have developed unusual fractures in their thigh bone. Symptoms of a fracture may include new or unusual pain in your hip, groin, or thigh. What is Reclast? Reclast is a prescription medicine used to: 5. Possible harm to your unborn baby. Reclast should not be used if you are pregnant. Tell your doctor right away if you are pregnant or plan to become pregnant. Reclast may harm your unborn baby. Call your doctor right away if you have any of these side effects. Bone, joint, or muscle pain Some people who take bisphosphonates develop severe bone, joint, or muscle pain. Reclast can cause serious side effects including: 1. Low calcium levels in your blood (hypocalcemia) 2. Course trians and the series of the questions about Reclast. do not have enough water in your body (dehydrated) before or after you receive Reclast Treat or prevent osteoporosis in women after menopause. Reclast helps reduce the chance of having a hip or spinal fracture (heak), increase bone mass in men with osteoporosis.
 Treat or prevent osteoporosis in either men or women Reclast<sup>®</sup> (RE-clast) (zoledronic acid) MEDICATION GUIDE Injection Have asthma (wheering) from taking aspirin.
 Plan to have dential surgery or teeth removed.
 Are pregnant, or plan to become pregnant. Reclass may harm your unborn baby. Reclass should not be used if you are present. Flu-like illness (lever, chills, bone, joint, or muscle pain fatigue) Have been told you have trouble absorbing minerals in your stomach or intestines (malabsorption syndrome) or have had parts of your intestine removed. who will be taking corticosteroid medicines for at least one year. • Treat certain men and women who have Paget's disease of the bone. The most common side effects of Reclast included Especially tell your doctor if you are taking: • An antibiotic Certain antibiotic medicines called antinoglyosoidas may increase the effect of hedast in lowering your toload calcium for a long period of time. • A diurelic or "water pill". Who should not take Reclast? Do not take Reclast if you: It is not known how long Reclast works for the treatment and prevention of ostepporosis. You should see your doctor regularly to determine if Reclast is still right for you. Reclast is not for use in children. What are the possible side effects of Reclast? Reclast may cause serious side effects. How will I receive Reclast? • Your doctor will tell you how often you will rèceive Reclast. Non-steroidal anti-inflammatory medicines (NSAIDS).
 Ask your doctor or pharmacist for a list of these medicines, if you are not sure. Vomiting
 Diarrhea your doctor. You may eat before your treatment with Reclast. If you miss a dose of Reclast, call your doctor or healthcare provider to schedule your next dose. Pain in your bones, joints or muscles Pain in your arms and leas now the medicines you take. Keep a list of them and how it to your doctor and pharmacist each time you get a See "What is the most important information I should know about Reclast?" Before you receive Reclast, drink at least 2 glasses of fluid (such as water) within a few hours as directed by IAAA. Reclast is given by infusion into your vein (intravenously). Your infusion should last at least 15 inutes.

C Novartis

2078648 US

 Hope low levels of calcium in your blood
 Hop low low constraints and the low low constraints and the low low constraints and the low low constraints and low 1 Take to your occur about hings you can do to help decrease some of news dee effects has might happen win a Bepasit induce 'You may pel alivities and so the twee or in rate cases, seeling of your fase, lies to your a of the to or that does not po away. These an ord all the sould be affect to that bothers you more is finanzian, ask your door or pharmadi. For many report does the redistal advice about olds an first. You many report side effects to FAA at 1.800-CD-A. 1088. **UNOVARTIS** This Medication Guide has been approved by the U.S. Food and Drug Administration. Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 What are the ingredients in Reclast? Active ingredient: zoledronic acid monohydrate For more information, go to: www.RECLAST.com or call 1-866-732-5278. Inactive ingredients: mannitol and sodium citrate. T2011-41/T2011-05 March 2011/January 2011